Clinical trials
Small Cell Lung Carcinoma trials in Belgium
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
68 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2000 | 1 |
| 2001 | 1 |
| 2002 | 2 |
| 2006 | 2 |
| 2007 | 2 |
| 2008 | 1 |
| 2009 | 1 |
| 2011 | 2 |
| 2013 | 2 |
| 2014 | 5 |
| 2015 | 2 |
| 2016 | 3 |
| 2017 | 4 |
| 2018 | 2 |
| 2019 | 3 |
| 2020 | 3 |
| 2021 | 6 |
| 2022 | 4 |
| 2023 | 4 |
| 2024 | 6 |
| 2025 | 5 |
| 2026 | 6 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 31 |
| Active, not recruiting | 12 |
| Recruiting | 12 |
| Terminated | 10 |
| Unknown status | 2 |
| Not yet recruiting | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Amgen | 9 |
| AbbVie | 6 |
| Boehringer Ingelheim | 6 |
| Bristol-Myers Squibb | 4 |
| Eli Lilly and Company | 3 |
| Hoffmann-La Roche | 3 |
| Incyte Corporation | 3 |
| Celgene | 2 |
| EMD Serono Research & Development Institute, Inc. | 2 |
| European Lung Cancer Working Party | 2 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Small Cell Lung Carcinoma | 68 |
| Carcinoma, Non-Small-Cell Lung | 9 |
| Carcinoma, Hepatocellular | 7 |
| Lung Neoplasms | 7 |
| Carcinoma, Merkel Cell | 5 |
| Carcinoma, Transitional Cell | 5 |
| Melanoma | 5 |
| Neoplasm Metastasis | 5 |
| Neoplasms | 5 |
| Carcinoma, Renal Cell | 4 |
Trials
Showing 51 to 68 of 68. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.